What A Leading Scientist Has to Say About Exosome Treatments in Aesthetics

As the landscape of aesthetic treatments continues to evolve, the latest exciting development has been the use of exosomes. 

Exosomes, tiny extracellular vesicles secreted by cells, play a crucial role in intercellular communication, making them a promising avenue for innovative aesthetic treatments. 

Cartessa Aesthetics’ cutting-edge Chronos series, headlined by our latest product, ExoCR, is at the forefront of this transformative trend delivering a new standard of excellence. ExoCR’s true potential was the subject of a wide-ranging webinar hosted by Cartessa, in which industry experts explained how the company’s treatment can revolutionize regenerative aesthetics. 

Advantages of Offering Exosome Treatments

“Traditionally in biologics, it’s really been cell-based therapeutics… and through further research, we began to understand that it’s not just the cells that have this therapeutic effect but also the signals that these cells make,” said Francisco Silva, lead scientist on ExoCR’s development, with more than 20 years of experience in the development and clinical translation of cell biologics-based therapies. 

This shift in focus from cell-based to exosome-based therapies presents a tremendous advantage in the realm of aesthetics, offering a versatile solution for a range of different patient needs.

“Inside of these microvesicles are different components, usually they’re highly rich in proteins, cytokines, and growth factors,” said Silva. “All of these elements play a role in communicating these messages to a cell. They’re critical to understanding mechanisms of action, and to better predict and engineer outcomes.”

Unlike stem cells, exosomes are devoid of cellular components, mitigating concerns related to potential immune reactions or uncontrolled cell growth. This characteristic makes exosome-based cosmetic treatments safer and less likely to provoke adverse responses, as they solely deliver bioactive molecules without the cellular structures that could trigger unwanted reactions.

Moreover, the source of exosomes, particularly those harvested from very young tissue like perinatal tissue, enhances their regenerative potential. Young tissue is less affected by free radicals and maintains a higher concentration of regenerative properties. 

The therapeutic potential of exosomes lies in their ability to regulate cellular processes and promote tissue repair. Unlike stem cell therapies, which involve the transplantation of live cells, exosome treatments utilize the signaling capabilities of these vesicles. By isolating and purifying exosomes from different sources, researchers and healthcare professionals can leverage their regenerative properties.

“We found that we can engineer these signals or engineer the cells that produce these signals to increase or decrease certain messages, depending on [what we want] the host cell to do to manipulate cellular responses,” Silva continued. “We essentially use exosomes to hijack this process and remodel the environment without having patients undergo potential scarring or prolonged downtime.” 

For context, exosomes have been used to reduce wrinkles, improve skin texture, and enhance skin elasticity, as well as to reduce inflammation and damage caused by UV radiation, according to MDPI, a major publisher of open-access scientific journals. They also help promote tissue regeneration in skin wounds and to treat several dermatological diseases. 

Benefits of Chronos’ ExoCR for Your Patients

ExoCR, the pioneering product in the Chronos portfolio, is a potent, single-source biologic solution designed to target dermal fibroblasts and improve the appearance of skin. 

“True to Cartessa fashion we do our due diligence to make certain that everything we bring to our Cartessa customers increases their patient experience, patient efficacy, and provides the best value to our customers,” said Crystal Romano, President of Emerging Technologies for Cartessa.

“In order to meet these expectations, it really takes time to procure and develop a product that fits this profile, [and] I’m happy to say the ExoCR has exceeded our expectations,” Romano added.

Derived from Wharton’s jelly within umbilical cords, ExoCR is composed of non-lyophilized tissue that undergoes thorough safety testing for endotoxins and is validated to contain more than 50 billion particulates, 10 billion intact exosomes, and over 1000 growth factors and cytokines.

“We’ve selected umbilical cord tissue for a number of reasons. It’s one of the only sources of tissue that has a very high abundance of naturally occurring exosomes that can be used for production, and just as important is the age of the material,” continued Silva. “Umbilical cord-derived material is essentially day zero from a developmental point of view, so it’s very potent, very enriched as opposed to [exosome] material that is older.” 

“ExoCR and the Chronos line enhance [microneedling] treatments to take your patient’s skin back in time, move up your treatment milestones, and work that magic.”  

Dedicated to ensuring traceability, purity, and potency, the Chronos line signifies a significant advancement in exosome technology. 

Meticulously formulated in a cutting-edge FDA-compliant, ISO 7, cGMP-certified facility, ExoCR is produced to the highest safety and compliance standards,  

Practitioners can rely on Cartessa to offer safe and highly effective solutions for their patients. 

Experience the epitome of groundbreaking exosome technology with Chronos ExoCR—now available for pre-ordering. 

Elevate your practice with Cartessa's state-of-the-art aesthetic and cosmetic solutions. Contact Cartessa today to learn more.